WO2006085122A2 - Biomarqueurs et leurs utilisations - Google Patents

Biomarqueurs et leurs utilisations Download PDF

Info

Publication number
WO2006085122A2
WO2006085122A2 PCT/GB2006/050035 GB2006050035W WO2006085122A2 WO 2006085122 A2 WO2006085122 A2 WO 2006085122A2 GB 2006050035 W GB2006050035 W GB 2006050035W WO 2006085122 A2 WO2006085122 A2 WO 2006085122A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
vgf
disorder
fragment
Prior art date
Application number
PCT/GB2006/050035
Other languages
English (en)
Inventor
Sabine Bahn
Jeffrey Huang
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of WO2006085122A2 publication Critical patent/WO2006085122A2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to peptide biomarkers for schizophrenic disorders bipolar disorders and related psychotic disorders. Biomarkers and methods in which they are employed can be used to assist diagnosis or to assess onset and development of a schizophrenic, bipolar or related psychotic disorder. The invention also relates to use of biomarkers in clinical screening, assessment of prognosis, evaluation of therapy, and for drug screening and drug development in the field of schizophrenic, bipolar and related psychotic disorders.
  • Schizophrenia is a major psychiatric disorder affecting up to 1 % of the population. It is found at similar prevalence in both sexes and is found throughout diverse cultures and geographic areas (1 ; 2).
  • the World Health Organization found schizophrenia to be the world's fourth leading cause of disability (3; 4) that accounts for 1.1 % of the total DALYs (Disability Adjusted Life Years) and 2.8% of YLDs ⁇ years of life lived with disability)(4). It was estimated that the economic cost of schizophrenia exceeded US$ 19 billion in 1991 , more than the total cost of all cancers in the United States. Effective treatments used early in the course of schizophrenia can improve prognosis and help reduce the costs associated with this illness.
  • the clinical syndrome of schizophrenia comprises discrete clinical features including positive symptoms (hallucination, delusions, disorganization of thought and unusual behaviour); negative symptoms (loss of motivation, restricted range of emotional experience and expression and reduced hedonic capacity); and cognitive impairments with extensive variation between individuals (5). No single symptom is unique to schizophrenia and/or is present in every case. Despite the lack of homogeneity of clinical symptoms, the current diagnosis and classification of schizophrenia is still based on the clinical symptoms presented by a patient (6). This is primarily because the aetiology of schizophrenia remains unknown (in fact, the aetiology of most psychiatric diseases is still unclear) and ciassification based on aetiology is as yet not feasible. The clinical symptoms of schizophrenia are often similar to symptoms observed in other neuropsychiatric and neurodevelopmental disorders.
  • the ICD-10 Classification of Mental and Behavioural Disorders published by the World Health Organization in 1992, is the manual most commonly used by European psychiatrists to diagnose mental health conditions.
  • the manual provides detailed diagnostic guidelines and defines the various forms of schizophrenia: schizophrenia, paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, post- schizophrenic schizophrenia, residual schizophrenia and simple schizophrenia.
  • the Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM IV) published by the American Psychiatric Association, Washington D. C, 1994, has proven to be an authoritative reference handbook for health professionals both in the United Kingdom and in the United States in categorizing and diagnosing mental health problems. This describes the diagnostic criteria, subtypes, associated features and criteria for differentia! diagnosis of mental health disorders, including schizophrenia, bipolar disorder and related psychotic disorders.
  • A. Characteristic symptoms Two (or more) of the following, each present for a significant portion of time during a 1 -month period (or less if successfully treated): delusions, hallucinations, disorganized speech (e.g., frequent derailment or incoherence), grossly disorganized or catatonic behaviour, negative symptoms, i.e., affective flattening, alogia, or avolition. Onfy one Criterion A symptom is required if delusions are playful or hallucinations consist of a voice keeping up a running commentary on the person's behaviour or thoughts, or two or more voices conversing with each other.
  • the signs of the disturbance may be manifested by only negative symptoms or two or more symptoms listed in Criterion A present in an attenuated form (e.g., odd beliefs, unusual perceptual experiences).
  • D. Schizoaffective and Mood Disorder exclusion; Schizoaffective Disorder and Mood Disorder With Psychotic Features have been ruled out because either (1) no Major Depressive Episode, Manic Episode, or Mixed Episode have occurred concurrently with the active-phase symptoms; or (2) if mood episodes have occurred during active-phase symptoms, their total duration has been brief relative to the duration of the active and residual periods.
  • Substance/general medical condition exclusion The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition.
  • Paranoid Type A type of Schizophrenia in which the following criteria are met: preoccupation with one or more delusions or frequent auditory hallucinations. None of the following is prominent: disorganized speech, disorganized or catatonic behaviour, or flat or inappropriate affect. 2.
  • Catatonic Type A type of Schizophrenia in which the clinical picture is dominated by at least two of the following: motoric immobility as evidenced by catalepsy (including waxy flexibility) or stupor excessive motor activity (that is apparently purposeless and not influenced by external stimuli), extreme negativism (an apparently motiveless resistance to all instructions or maintenance of a rigid posture against attempts to be moved) or mutism, peculiarities of voluntary movement as evidenced by posturing (voluntary assumption of inappropriate or strange postures), stereotyped movements, prominent mannerisms, or prominent grimacing echolalia or echopraxia.
  • Disorganized Type A type of Schizophrenia in which the following criteria are met; all of the following are prominent: disorganized speech, disorganized behaviour, flat or inappropriate affect. The criteria are not met for Catatonic Type. 4. Undifferentiated Type; A type of Schizophrenia in which symptoms that meet Criterion A are present, but the criteria are not met for the Paranoid, Disorganized, or Catatonic Type.
  • Residual Type A type of Schizophrenia in which the following criteria are met: absence of prominent delusions, hallucinations, disorganized speech, and grossly disorganized or catatonic behaviour. There is continuing evidence of the disturbance, as indicated by the presence of negative symptoms or two or more symptoms listed in Criterion A for Schizophrenia, present in an attenuated form (e.g., odd beliefs, unusual perceptual experiences).
  • schizophrenia includes: learning problems, hypoactivity, psychosis, euphoric mood, depressed mood, somatic or sexual dysfunction, hyperactivity, guiit or obsession, sexually deviant behaviour, odd/eccentric or suspicious personality, anxious or fearful or dependent personality, dramatic or erratic or antisocial personality.
  • schizophrenia psychotic disorder due to a general medical condition, delirium, or dementia; substance-induced psychotic disorder; substance-induced delirium; substance- induced persisting dementia; substance-related disorders; mood disorder with psychotic features; schizoaffective disorder; depressive disorder not otherwise specified; bipolar disorder not otherwise specified; mood disorder with catatonic features; schizophreniform disorder; brief psychotic disorder; delusional disorder; psychotic disorder not otherwise specified; pervasive developmental disorders ⁇ e.g., autistic disorder); childhood presentations combining disorganized speech (from a communication disorder) and disorganized behaviour (from attention-deficit/hyperactivity disorder); schizotypal disorder; schizoid personality disorder and paranoid personality disorder DSM IV Diagnostic categories for manic depress ⁇ on/bi-polar affective disorder (BD)
  • BD manic depress ⁇ on/bi-polar affective disorder
  • Bipolar ! This disorder is characterized by manic episodes; the 'high 1 of the manic-depressive cycle. Generally this manic period is followed by a period of depression, although some bipolar I individuals may not experience a major depressive episode. Mixed states, where both manic or hypomanic symptoms and depressive symptoms occur at the same time, aiso occur frequently with bipolar I patients (for example, depression with the racing thoughts of mania). Also, dysphoric mania is common, this is mania characterized by anger and irritability.
  • Bipolar II This disorder is characterized by major depressive episodes alternating with episodes of hypomania, a milder form of mania. Hypomanic episodes can be a less disruptive form of mania and may be characterized by iow-ievel, non-psychotic symptoms of mania, such as increased energy or a more elated mood than usual. It may not affect an individual's ability to function on a day to day basis. The criteria for hypomania differ from those for mania only by their shorter duration (at least 4 days instead of 1 week) and milder severity (no marked impairment of functioning, hospitalization or psychotic features).
  • Cyclothymic disorder is diagnosed over the course of two years and is characterized by frequent short periods of hypomania and depressive symptoms separated by periods of stability. Rapid cycling occurs when an individual's mood fluctuates from depression to hypomania or mania in rapid succession with little or no periods of stability in between. One is said to experience rapid cycling when one has had four or more episodes, in a given year, that meet criteria for major depressive, manic, mixed or hypomanic episodes. Some people who rapid cycle can experience monthly, weekly or even daily shifts in polarity (sometimes called ultra rapid cycling).
  • a manic mood is brought about through an antidepressant, ECT or through an individual using street drugs, the diagnosis is Substance-Induced Mood Disorder, with Manic Features.
  • Diagnosis of Bipolar II! has been used to categorise manic episodes which occur as a result of taking an antidepressant medication, rather than occurring spontaneously. Confusingly, it has also been used in instances where an individual experiences hypomania or cyclothymia (i.e. less severe mania) without major depression.
  • Manic Depression is comprised of two distinct and opposite states of mood, whereby depression alternates with mania.
  • the DSM IV gives a number of criteria that must be met before a disorder is classified as mania. The first one is that an individual's mood must be elevated, expansive or irritable. The mood must be a different one to the individual's usual affective state during a period of stability. There must be a marked change over a significant period of time. The person must become very elevated and have grandiose ideas. They may also become very irritated and may well appear to be 'arrogant' in manner.
  • the second main criterion for mania emphasizes that at least three of the following symptoms must have been present to a significant degree: inflated sense of self importance, decreased need for sleep, increased talkativeness, flight of ideas or racing thoughts, easily distracted, increased goal-directed activity. Excessive involvement in activities that can bring pleasure but may have disastrous consequences (e.g. sexual affairs and spending excessively).
  • the third criterion for mania in the DSM IV emphasizes that the change in mood must be marked enough to affect an individual's job performance or ability to take part in regular social activities or relationships with others. This third criterion is used to emphasize the difference between mania and hypomania.
  • the DSM IV states that there are a number of criteria by which major depression is clinically defined. The condition must have been evident for at least two weeks and must have five of the following symptoms: a depressed mood for most of the day, almost every day, a ioss of interest or pleasure in almost all activities, almost every day, changes in weight and appetite, sleep disturbance, a decrease in physical activity, fatigue and loss of energy, feelings of worthlessness or excessive feelings of guilt, poor concentration levels, suicidal thoughts.
  • Psychosis is characterized by disorders in basic perceptual, cognitive, affective, and judgmental processes. Persons experiencing a psychotic episode may experience hallucinations (often auditory or visual hallucinations), hold paranoid or delusional beliefs, experience personality changes and exhibit disorganised thinking (see thought disorder). This is sometimes accompanied by features such as a lack of insight into the unusual or playful nature of their behaviour, difficulties with social interaction and impairments in carrying out the activities of daily living.
  • Psychosis is usually considered by mainstream psychiatry to be a symptom of severe mental illness. Although it is not exclusively linked to any particular psychological or physical state, it is particularly associated with schizophrenia, bipolar disorder (manic depression) and severe clinical depression.
  • Psychosis is not uncommon in cases of brain injury and may occur after drug use, particularly after drug overdose or chronic use; certain compounds may be more iikely to induce psychosis and some individuals may show greater sensitivity than others.
  • the direct effects of hallucinogenic drugs are not usually classified as psychosis, as long as they abate when the drug is metabolised from the body.
  • Chronic psychological stress is also known to cause psychotic states, however the exact mechanism is uncertain.
  • Psychosis triggered by stress in the absence of any other mental illness is known as brief reactive psychosis.
  • Psychosis is thus a descriptive term for a complex group of behaviours and experiences. Individuals with schizophrenia can have long periods without psychosis and those with bipolar disorder, or depression, can have mood symptoms without psychosis.
  • Hallucinations are defined a sensory perception in the absence of externa! stumuli.
  • Psychotic hallucinations may occur in any of the five senses and can take on almost any form, which may include simple sensations (such as lights, colours, tastes, smells) to more meaningful experiences such as seeing and interacting with fully formed animals and people, hearing voices and complex tactile sensations.
  • Auditory hallucination particularly the experience of hearing voices, is a common and often prominent feature of psychosis. Hallucinated voices may talk about, or to the person, and may involve several speakers with distinct personas. Auditory haliucinations tend to be particularly distressing when whey are derogatory, commanding or preoccupying.
  • Psychosis may involve delusional or paranoid beliefs, classified into primary and secondary types.
  • Primary delusions are defined as arising out-of-the-blue and not being comprehensible in terms of normal mental processes, whereas secondary delusions may be understood as being influenced by the person's background or current situation.
  • Psychosis may be the result of an underlying mental illness such as bipolar disorder (manic depression), or schizophrenia. Psychosis may also be triggered or exacerbated by severe mental stress and high doses or chronic use of drugs such as amphetamines, LSD, PCP, cocaine or scopolamine.
  • drugs such as amphetamines, LSD, PCP, cocaine or scopolamine.
  • incidence of psychosis resulting from a single administration of any drug is rare, although cases have been reported in the medical literature suggesting a person's sensitivities to new compounds can be unpredictable.
  • Psychosis has been reported in a wide variety of illnesses and conditions including for example, AIDS, leprosy, malaria and even mumps. No singular cause of a psychotic episode has been identified to date.
  • Psychotic episodes may vary in duration between individuals. In brief reactive psychosis, the psychotic episode is related directly to a specific stressful life event, so patients may spontaneously recover normal functioning within two weeks. In some rare cases, individuals may remain in a state of full blown psychosis for many years, or perhaps have attenuated psychotic symptoms (such as low intensity hallucinations) present at most times.
  • Patients who are undergoing a brief psychotic episode may have many of the same symptoms as a person who is psychotic as a result of (for example) schizophrenia, and this fact has been used to support the notion that psychosis is primarily a breakdown in some specific biological system in the brain.
  • WO 01/63294 describes methods and compositions for screening, diagnosis, and determining prognosis of neuropsychiatry or neurological conditions (including BAD (bipolar affective disorder), schizophrenia and vascular dementia), for monitoring the effectiveness of treatment in these conditions and for use in drug development
  • the VGF gene encodes a neuropeptide precursor which is expressed in a subset of neurons in the central and peripheral nervous system and in specific populations of endrocrine ceils found in the adenohypophysis, adrenal medulla, gastrointestinal tract and pancreas. Expression of VGF is upregulated in responsive neurons by neurotrophins. VGF is a recognised nerve growth factor and plays an essential role in the regulation of energy homeostasis.
  • the human VGF protein is 615 amino acids in length; the VGF protein in mouse and rat is 617 amino acids in length. There is about 85% homology between the human and rat VGF proteins.
  • the VGF neuropeptide precursor has a secretory leader ("signal") sequence of 22 amino acids that promotes translocation into the endoplasmic reticulum, in the VGF neuropeptide precursor and the mature full length VGF peptide cleaved from that precursor, there are numerous short stretches of basic amino acid residues, which are potential target sites for peptidase cleavage resulting in the generation of shorter VGF peptides.
  • signal secretory leader
  • VGF peptides have been identified in rat and human; Stark et al (2001) (17) identified three N-terminal fragments of VGF (amino acids 23 to 62, 26 to 62 (N-terminal truncation of peptide 23 to 62) and 23 to 59 (C-terminal truncation of peptide 23 to 62) in human cerebrospinal fluid (CSF) obtained from subjects without known neurological disorders.
  • CSF cerebrospinal fluid
  • VGF peptide biomarkers have been associated with chronic dementia diseases.
  • international Patent Application No PCT/DE02/01376 (WO 02/082075) describes methods for detecting chronic dementia diseases, in particular Alzheimer's disease, involving detection of various VGF-derived peptides, including VGF 23 to 62 and VGF 26 to 62. These diseases are organic disorders. Diagnosis of chronic dementia disease such as those described in WO 02/082075 automatically excludes diagnosis of psychotic disorders such as schizophrenic or bipolar disorder. Until now, there has been no report of a VGF peptide associated with psychotic disorders such as schizophrenic disorder, bipolar disorder or predisposition thereto.
  • the present invention provides the use of a VGF peptide, preferably consisting of the amino acid sequence shown in SEQ ID NO: 1 , or a fragment thereof, as a biomarker for a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto.
  • the invention further provides a VGF peptide biomarker for a schizophrenic disorder, bipolar disorder, related psychotic disorder or predisposition thereto, preferably consisting of the amino acid sequence shown in SEQ ID NO: 1 , or a fragment thereof.
  • biomarker means a distinctive biological or biologically derived indicator of a process, event, or condition.
  • Peptide biomarkers can be used in methods of diagnosis, e.g. clinical screening, and prognosis assessment and in monitoring the results of therapy, identifying patients most likely to respond to a particular therapeutic treatment, drug screening and development. Biomarkers and uses thereof are valuable for identification of new drug treatments and for discovery of new targets for drug treatment.
  • VGF peptide biomarker includes the mature full length human VGF peptide generated by cleavage of the signal sequence from the human VGF neuropeptide precursor.
  • Preferred VGF peptide biomarkers are peptides in which the N-terminus is generated by proteolytic cleavage of the putative secretory leader ("signal") sequence of VGF.
  • a particularly preferred VGF peptide biomarker (SEQ ID NO: 1) is derived from the human VGF protein, the biomarker consists of amino acids 23 to 62 of VGF. This biomarker amino acid sequence is found immediately following the carboxyl terminus of the putative signal peptide in human VGF protein ( Figure 3).
  • the peptide biomarker as shown in SEQ ID NO: 1 ( Figure 2) is found to be present at elevated levels in individuals with first onset psychosis characteristic of schizophrenic or bipolar disorders, it is thus useful as a marker for diagnosing and monitoring schizophrenic disorders, bipolar disorder, related psychotic disorders, or predisposition thereto.
  • related psychotic disorder refers to neuropsychiatry (psychotic depression and other psychotic episodes) and neurodevelopmental disorders (especially Autistic spectrum disorders) which can present with psychotic or other schizophrenia-like symptoms.
  • the invention provides a method of diagnosing or monitoring a schizophrenic disorder, bipolar disorder, related psychotic disorder or predisposition thereto, comprising detecting and/or quantifying a VGF peptide biomarker, preferably consisting of the amino acid sequence of SEQ ID NO: 1 , or a fragment thereof, present in a biological sample from a test subject.
  • Monitoring methods of the invention can be used to monitor onset, progression, stabilisation, amelioration and/or remission.
  • detecting and/or quantifying the peptide biomarker in a biological sample from a test subject may be performed on two or more occasions. Comparisons may be made between the level of biomarker in samples taken on two or more occasions. Assessment of any change in the level of peptide biomarker in samples taken on two or more occasions may be performed. Modulation of the peptide biomarker level is useful as an indicator of the state of the schizophrenic disorder, bipolar disorder, related psychotic disorder or predisposition thereto. An increase in the level of peptide biomarker over time is indicative of onset or progression, i.e. worsening of this disorder, whereas a decrease in the level of peptide biomarker indicates amelioration or remission of the disorder.
  • a method of diagnosis of or monitoring according to the invention may comprise quantifying a VGF peptide biomarker, preferably consisting of the amino acid sequence of SEQ ID NO: 1 , or a fragment thereof, in a test biological sample from a test subject and comparing the level of peptide present in said test sample with one or more controls.
  • the control used in a method of the invention can be one or more control(s) selected from the group consisting of: the level of biomarker found in a normal control sample from a normal subject, a normal biomarker level; a normal biomarker range, the level in a sample from a subject with a schizophrenic disorder, bipolar disorder, related psychotic disorder, or a diagnosed predisposition thereto; a schizophrenic disorder marker level, a bipolar disorder marker level, a related psychotic disorder marker level, a schizophrenic disorder marker range, a bipolar disorder marker range and a related psychotic disorder marker range.
  • a preferred method of diagnosing a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto comprises:
  • VGF peptide biomarker preferably consisting of SEQ ID NO: 1 , or a fragment thereof
  • a higher level of the VGF peptide biomarker in the test sample relative to the level in the normal control is indicative of the presence of a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto.
  • An equivalent or lower level of said peptide in the test sample relative to the normal control is indicative of absence of a schizophrenic disorder, absence of a bipolar disorder, absence of a related psychotic disorder and/or absence of a predisposition thereto.
  • diagnosis encompasses identification, confirmation, and/or characterisation of a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto.
  • predisposition it is meant that a subject does not currently present with the disorder, but is liable to be affected by the disorder in time.
  • Methods of monitoring and of diagnosis according to the invention are useful to confirm the existence of a disorder, or predisposition thereto; to monitor development of the disorder by assessing onset and progression, or to assess ameiioration or regression of the disorder.
  • Methods of monitoring and of diagnosis are also useful in methods for assessment of clinical screening, prognosis, choice of therapy, evaluation of therapeutic benefit, i.e. for drug screening and drug development.
  • Efficient diagnosis and monitoring methods provide very powerful "patient solutions” with the potential for improved prognosis, by establishing the correct diagnosis, allowing rapid identification of the most appropriate treatment (thus lessening unnecessary exposure to harmful drug side effects), reducing "down- time” and relapse rates.
  • test samples may be taken on two or more occasions.
  • the method may further comprise comparing the level of the biomarker present in the test sample with one or more control(s) and/or with one or more previous test samp!e(s) taken earlier from the same test subject, e.g. prior to commencement of therapy, and/or from the same test subject at an earlier stage of therapy.
  • the method may comprise detecting a change in the level of the biomarker in test samples taken on different occasions.
  • the invention provides a method for monitoring efficacy of therapy for a schizophrenic, bipolar or related psychotic disorder in a subject, comprising:
  • VGF peptide biomarker preferably consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, in a test biological sample taken from said subject, and
  • a decrease in the level of the peptide biomarker in the test sample relative to the level in a previous test sample taken earlier from the same test subject is indicative of a beneficial effect, e.g. stabilisation or improvement, of said therapy on the disorder, suspected disorder or predisposition thereto.
  • Methods for monitoring efficacy of a therapy can be used to monitor the therapeutic effectiveness of existing therapies and new therapies in human subjects and in non-human animals (e.g. in animal models). These monitoring methods can be incorporated into screens for new drug substances and combinations of substances.
  • the time elapsed between taking samples from a subject undergoing diagnosis or monitoring will be 3 days, 5 days, a week, two weeks, a month, 2 months, 3 months, 6 or 12 months.
  • Samples may be taken prior to and/or during and/or following an anti-schizophrenic, anti-bipolar or other anti-psychotic disorder therapy. Samples can be taken at intervals over the remaining life, or a part thereof, of a subject.
  • detecting means confirming the presence of a VGF peptide biomarker, preferably consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, present in the sample.
  • Quantifying the amount of the biomarker present in a sample may include determining the concentration of the peptide biomarker present in the sample. Detecting and/or quantifying may be performed directly on the sample, or indirectly on an extract therefrom, or on a dilution thereof.
  • the presence of the peptide biomarker is assessed by detecting and/or quantifying antibody or fragments thereof capable of specific binding to the biomarker that are generated by the subject's body in response to the peptide and thus are present in a biological sample from a subject having a schizophrenic disorder, bipolar disorder, related psychotic disorder or predisposition thereto.
  • Detecting and/or quantifying can be performed by any method suitable to identify the presence and/or amount of a specific protein in a biological sample from a patient or a purification of extract of a biological sample or a dilution thereof.
  • quantifying may be performed by measuring the concentration of the VGF peptide biomarker in the sample or samples.
  • Biological samples that may be tested in a method of the invention include cerebrospinal fluid (CSF), whole blood, blood serum, urine, saliva, or other bodily fluid (stool, tear fluid, synovial fluid, sputum), breath, e.g. as condensed breath, or an extract or purification therefrom, or diiution thereof.
  • Biological samples also include tissue homogenates, tissue sections and biopsy specimens from a live subject, or taken post-mortem.
  • the samples can be prepared, for example where appropriate diluted or concentrated, and stored in the usual manner.
  • Detection and/or quantification of VGF peptide biomarkers may be performed by detection of the peptide biomarker or of a fragment thereof, e.g. a fragment with C-terminal truncation, or with N-terminal truncation. Fragments are suitably greater than 4 amino acids in length.
  • the biornarker may be directly detected, e.g. by SELDI, MALDJ-TOF.
  • the biomarker may be detected directly or indirectly via interaction with a ligand or ligands such as an antibody or a biomarker-binding fragment thereof, or other peptide, or ligand, e.g. aptamer, or oligonucleotide, capable of specifically binding the biomarker.
  • the ligand may possess a detectable label, such as a luminescent, fluorescent or radioactive iabel, and/or an affinity tag.
  • detecting and/or quantifying can be performed by one or more method(s) selected from the group consisting of: SELDi (-TOF) 1 MALDI (-TOF) 1 a 1-D gel-based analysis, a 2-D gel-based analysis, Mass spec (MS) and LC- MS-based techniques.
  • Appropriate LC MS techniques include ICAT® (Applied Biosystems, CA, USA) , or iTRAQ® (Applied Biosystems, CA, USA).
  • Liquid chromatography e.g. high pressure liquid chromatography (HPLC) or iow pressure liquid chromatography (LPLC)
  • thin-layer chromatography e.g. high pressure liquid chromatography (HPLC) or iow pressure liquid chromatography (LPLC)
  • NMR nuclear magnetic resonance
  • CSF cerebrospinal fluid
  • SELDI TOF SELDI TOF
  • MALD! TOF a sample of cerebrospinal fluid
  • Detecting and/or quantifying the VGF peptide biomarker may be performed using an immunological method, involving an antibody, or a fragment thereof capable of specific binding to the VGF peptide biomarker, e.g. to a peptide consisting of the amino acid sequence shown in SEQ iD NO: 1 or a fragment thereof.
  • Suitable immunological methods include sandwich immunoassays, such as sandwich ELISA 1 in which the detection of the peptide biomarkers is performed using two antibodies which recognize different epitopes on the peptide biomarker; radioimmunoassays (RIA) 1 direct or competitive enzyme linked immunosorbent assays (ELiSA) 1 enzyme immuno assays (EIA), western blotting, immunoprecipitatton and any particle-based immunoassay (e.g. using gold, silver, or latex particles, magnetic particles, or Q-dots).
  • sandwich immunoassays such as sandwich ELISA 1 in which the detection of the peptide biomarkers is performed using two antibodies which recognize different epitopes on the peptide biomarker
  • RIA radioimmunoassays
  • ELiSA enzyme immuno assays
  • western blotting immunoprecipitatton
  • immunoprecipitatton e.g. using gold, silver, or latex particles, magnetic particles, or Q-
  • antibody as used herein includes, but is not limited to: polyclonal, monoclonal, bispecific, humanised or chimeric antibodies, single chain antibodies, Fab fragments and F (ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • antibody as used herein also refers to immunoglobulin molecules and immunologicaliy-active portions of immunoglobulin molecules, i. e., molecules that contain an antigen binding site that specifically binds an antigen.
  • the immunoglobulin molecules of the invention can be of any class (e. g., IgG, IgE, igM, IgD and IgA) or subclass of immunoglobulin molecule.
  • biosensors appropriate diagnostic tools such as biosensors can be developed, accordingly, in methods and uses of the invention, detecting and quantifying can be performed using a biosensor.
  • the biosensor may incorporate an immunological method for detection of the biomarker, an electrical, thermal, magnetic, optical (e.g. hologram) or acoustic technologies. Using such biosensors, it is possible to detect the target biomarker at the anticipated concentrations found in biological samples.
  • the biomarker of the invention can be detected using a biosensor incorporating technologies based on "smart" holograms, or high frequency acoustic systems, such systems are particularly amenable to "bar code” or array configurations.
  • a biosensor incorporating technologies based on "smart" holograms, or high frequency acoustic systems, such systems are particularly amenable to "bar code” or array configurations.
  • smart hologram sensors Smart Holograms Ltd, Cambridge, UK
  • a holographic image is stored in a thin polymer film that is sensitised to react specifically with the biomarker.
  • the biomarker reacts with the polymer leading to an alteration in the image displayed by the hologram.
  • the test result read-out can be a change in the optical brightness, image, colour and/or position of the image.
  • a sensor hologram can be read by eye, thus removing the need for detection equipment.
  • a simple colour sensor can be used to read the signal when quantitative measurements are required. Opacity or colour of the sample does not interfere with operation of the sensor.
  • the format of the sensor allows multiplexing for simultaneous detection of several substances. Reversible and irreversible sensors can be designed to meet different requirements, and continuous monitoring of a particular biomarker of interest is feasible.
  • biosensors for detection of the biomarker of the invention combine biomolecular recognition with appropriate means to convert detection of the presence, or quantitation, of the biomarker in the sample into a signal.
  • Biosensors can be adapted for "alternate site” diagnostic testing, e.g. in the ward, outpatients' department, surgery, home, field and workplace.
  • Biosensors to detect the biomarker of the invention include acoustic, plasmon resonance, holographic and microengineered sensors. Imprinted recognition elements, thin film transistor technology, magnetic acoustic resonator devices and other novel acousto-electrical systems may be employed in biosensors for detection of the biomarkers of the invention.
  • Methods involving detection and/or quantification of the peptide biomarker of the invention can be performed on bench-top instruments, or can be incorporated onto disposable, diagnostic or monitoring platforms that can be used in a non-laboratory environment, e.g. in the physician's office or at the patient's bedside.
  • Suitable biosensors for performing methods of the invention include "credit" cards with optical or acoustic readers. Biosensors can be configured to allow the data collected to be electronically transmitted to the physician for interpretation and thus can form the basis for e-neuromedicine.
  • the level of peptide of SEQ ID NO: 1 detected in a sample from a test subject with a schizophrenic disorder, bipolar disorder, related psychotic disorder or predisposition thereto will generally be greater than 2.5-fold or higher, e.g.
  • a further aspect of the invention provides ligands, such as naturally occurring or chemically synthesised compounds, capable of specific binding to the VGF peptide biomarker.
  • a ligand according to the invention may comprise a peptide, an antibody or a fragment thereof, or an aptamer or oligonucleotide, capable of specific binding to the VGF peptide biomarker.
  • the antibody can be a monoclonal antibody or a fragment thereof capable of specific binding to the VGF peptide biomarker.
  • a ligand according to the invention may be labelled with a detectable marker, such as a luminescent, fluorescent or radioactive marker; alternatively or additionally a ligand according to the invention may be labelled with an affinity tag.
  • Biosensors according to the invention may comprise a ligand or ligands, as described herein, capable of specific binding to the VGF peptide biomarker. Such biosensors are useful in detecting and/or quantifying a peptide of the invention.
  • a biosensor according to the invention may comprise the VGF peptide biomarker, or a structural/shape mimic thereof capable of specific binding to an antibody against the VGF peptide biomarker.
  • an array comprising a ligand as described herein capable of specific binding to the VGF peptide biomarker, or an array comprising the VGF peptide biomarker or a structural/shape mimic thereof.
  • kits for performing methods of the invention.
  • kits will suitably comprise a ligand according to the invention, for detection and/or quantification of the VGF peptide biomarker, and/or a biosensor, and/or an array as described herein, optionally together with instructions for use of the kit.
  • a ligand as described herein which may be naturally occurring or chemically synthesised, and is suitably a peptide, antibody or fragment thereof, aptamer or oligonucleotide, or the use of a biosensor of the invention, or an array of the invention, or a kit of the invention to detect and/or quantify the VGF peptide biomarker or a fragment thereof.
  • the detection and/or quantification can be performed on a biological sample such as from the group consisting of CSF, whole blood, blood serum, urine, saliva, or other bodily fluid, breath, e.g. as condensed breath, or an extract or purification therefrom, or dilution thereof.
  • Biomarkers for a schizophrenic disorders, bipolar disorders and related psychotic disorders are essential targets for discovery of novel targets and drug molecules that retard or halt disease progression.
  • the biomarker is useful for identification of novel therapeutic compounds in in vitro and/or in vivo assays.
  • the biornarker of the invention can be employed in methods for screening for compounds that modulate the activity of, or suppress the generation of, a VGF peptide biomarker according to the invention,
  • a ⁇ gand as described, which can be a peptide, antibody or fragment thereof or aptamer or oligonucleotide according to the invention; or the use of a biosensor according to the invention, or an array according to the invention; or a kit according to the invention, to identify a substance capable of suppressing the generation of a VGF peptide biomarker.
  • a method of identifying a substance capable of suppressing the generation of a VGF peptide biomarker comprising administering a test substance to a subject animal and detecting and/or quantifying levels of the peptide biomarker present in a test sample from the subject.
  • Any suitable animal may be used as a subject non-human animal, for example a non-human primate, horse, cow, pig, goat, sheep, dog, cat, fish, rodent, e.g. guinea pig, rat or mouse; insect (e.g. Drosophila), amphibian (e.g. Xenopus) or C. elegans.
  • a non-human primate horse, cow, pig, goat, sheep, dog, cat, fish
  • rodent e.g. guinea pig, rat or mouse
  • insect e.g. Drosophila
  • amphibian e.g. Xenopus
  • C. elegans e.g. Xenopus
  • the test substance can be a known chemical or pharmaceutical substance, such as, but not limited to, an anti-schizophrenic or anti-bipolar disorder therapeutic, a known anti-psychotic; or the test substance can be novel synthetic or natural chemical entity, or a combination of two or more of the aforesaid substances.
  • a method of identifying a substance capable of suppressing the generation of a VGF peptide biomarker preferably consisting of the amino acid sequence of SEQ ID NO: 1 , or a fragment thereof, in a subject, comprising exposing a test ceil to a test substance and monitoring levels of the VGF peptide biomarker within said test cell, or secreted by said test cell.
  • the test cell could be prokaryotic, however it is preferred that a eukaryotic cell be employed in cell-based testing methods.
  • the eukaryotic cell is a yeast cell, insect cell, Drosophila cell, amphibian ceil (e.g. from Xenopus), C. elegans cell or is a cell of human, non-human primate, equine, bovine, porcine, caprine, ovine, canine, feline, piscine, rodent or murine origin.
  • non-human animals or cells that are capable of expressing one or more polypeptide selected from the group consisting of human VGF polypeptides and proteolytic enzymes, preferably human proteolytic enzymes capable of cleaving a human VGF polypeptide.
  • Screening methods also encompass a method of identifying a ligand capable of binding to a VGF peptide biomarker according to the invention, comprising incubating a test substance in the presence of the peptide biomarker in conditions appropriate for binding, and detecting and/or quantifying binding of the peptide to said test substance.
  • VGF peptide biomarker is a peptide consisting of the sequence of SEQ ID NO: 1 (human VGF amino acids 23 to 62, or a fragment thereof)
  • specific binding is indicated if the test substance does not bind to mature full length human VGF protein or to a protein consisting of amino acids 26 to 62 of human VGF (N-terminal 3 peptide truncated sequence).
  • High-throughput screening technologies based on the biomarker, uses and methods of the invention are suitable to monitor biomarker signatures for the identification of potentially useful therapeutic compounds, e.g. ligands such as natural compounds, synthetic chemical compounds (e.g. from combinatorial libraries), peptides, monoclonal or polyclonal antibodies or fragments thereof, capable of binding the biomarker.
  • Methods of the invention can be performed in array format, e.g. on a chip, or as a muitiwell array. Methods can be adapted into platforms for single tests, or multiple identical or multiple non-identical tests, and can be performed in high throughput format. Methods of the invention may comprise performing one or more additional, different tests to confirm or exclude diagnosis, and/or to further characterise a condition.
  • the invention further provides a substance, e.g. a ligand, identified or identifiable by an identification or screening method or use of the invention.
  • a substance e.g. a ligand
  • Such substances may be capable of inhibiting, directly or indirectly, the activity of a VGF peptide biomarker, or of suppressing generation of the VGF peptide biomarker.
  • the term "substances” includes substances that do not directly bind the VGF peptide biomarker and directly inhibit a function, but instead indirectly inhibit a function of the VGF peptide biomarker.
  • Ligands are also included in the term substances; ligands of the invention (e.g. a natural or synthetic chemical compound, peptide, aptamer, oligonucleotide, antibody or antibody fragment) are capable of binding, preferably specific binding, to a VGF peptide biomarker.
  • the invention further provides the use of a substance or ligand according to the invention in the treatment of a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto.
  • kits for diagnosing or monitoring a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto are provided.
  • a kit according to the invention may contain one or more components selected from the group: a ligand specific for a VGF peptide biomarker, a VGF peptide biomarker or a structural/shape mimic of a VGF peptide biomarker, a control(s), a reagent(s), and a consumable(s); optionally together with instructions for use of the kit.
  • biomarkers for schizophrenic disorders, bipolar disorders and related psychotic disorders permits integration of diagnostic procedures and therapeutic regimes.
  • many anti-schizophrenic, bipolar disorder and anti-psychotic therapies have required treatment trials lasting weeks to months for a given therapeutic approach.
  • Detection of a VGF peptide biomarker of the invention can be used to screen subjects prior to their participation in clinical trials.
  • the biomarker provides a means to indicate therapeutic response, failure to respond, unfavourable side-effect profile, degree of medication compliance and achievement of adequate serum drug levels.
  • the biomarker may be used to provide warning of adverse drug response, a major problem encountered with all psychotropic medications.
  • Biomarkers are useful in development of personalized brain therapies, as assessment of response can be used to fine-tune dosage, minimise the number of prescribed medications, reduce the delay in attaining effective therapy and avoid adverse drug reactions.
  • patient care can be tailored precisely to match the needs determined by the disorder and the pharmacogenomic profile of the patient, the biomarker can thus be used to titrate the optimal dose, predict a positive therapeutic response and identify those patients at high risk of severe side effects.
  • Biomarker based tests provide a first line assessment of 'new' patients, and provide objective measures for accurate and rapid diagnosis, in a time frame and with precision, not achievable using the current subjective measures.
  • diagnostic biomarker tests are useful to identify family members or patients in the "prodromal phase", i.e. those at high risk of developing overt schizophrenia, bipolar disorder, or related psychotic disorder. This permits initiation of appropriate therapy, for example low dose antipsychotics, or preventive measures, e.g. managing risk factors such as stress, illicit drug use, or viral infections. These approaches are recognised to improve outcome and may prevent overt onset of the disorder.
  • Biomarker monitoring methods, biosensors and kits are also vital as patient monitoring tools, to enable the physician to determine whether relapse is due to a genuine breakthrough or worsening of the disease, poor patient compliance or substance abuse. If pharmacological treatment is assessed to be inadequate, then therapy can be reinstated or increased. For genuine breakthrough disease, a change in therapy can be given if appropriate. As the biomarker is sensitive to the state of the disorder, it provides an indication of the impact of drug therapy or of substance abuse.
  • FIG. 1 The biomarker (a peptide of SEQ ID NO: 1) in CSF at 3.96kDa.
  • Cerebrospinal fluid (CSF) samples from 40 healthy volunteers and from 40 untreated subjects with first onset psychosis were included in this study. An aliquot of 5 ⁇ l of each CSF sample was applied to each of the protein chips tested ⁇ each having different chemical properties) at various pH conditions. The best conditions were found to be at pH 9.0 on strong anion exchanger Q10 chip, the selection of these parameters was based on the number and separation of peaks resolved.
  • the protein/peptides bound to the chip surface were then analysed by SELD! mass spectrometry. An example of a spectrum from a healthy volunteer is shown in Fig 1A.
  • FIG. 1 Identification of the 3.96kDa peptide of SEQ ID NO: 1 as a VGF fragment.
  • Samples of 50 ⁇ l of the CSFs with highest expression of 3.96kDa peak were processed with 10kDa cut-off column to remove large proteins.
  • the flow-through was then desalted using a C18 Ziptip (Millipore, Bhavericak, USA) and the peptides were eluted with 0.1% formic acid/50% aqueous acetonitrile.
  • Aliquots of 1 ⁇ l of the eluate were loaded directly into a nanospray tip for ESl- MS/MS (for de novo sequencing) and SELDI mass spectrometers (for the confirmation of the enriched 3.96kDa peak).
  • FIG. 3 Mapping the peptide biomarker to VGF protein.
  • A. The peptide of 3.96kDa (or 3.95kDa from ESI-MS/MS spectrum) was mapped to amino acids 23 to 62 (SEQ ID NO: 1) of the native VGF protein (in bold underlined), immediately next to a predicted secretary signal peptide (using InterProScan: European Bioinformatics Institute: www.ebi.ac.uk/cgibin/iprscan).
  • This 3.96kDa peptide has the amino acid sequence shown in SEQ ID NO: 1 B, Sequence alignment of the 3.96kDa peptide and the 3.69kDa peptide.
  • FIG. 1 Western blotting analysis of mature full length human VGF peptide biomarker in the prefrontal cortex of age-matched controls and patients with schizophrenia.
  • the chips were then sequentially treated twice with 1 ⁇ l of a 100 % saturated sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) in 50 % acetonitrile and 0.5 % trifluoroacetic acid.
  • the chips were analyzed with the Ciphergen ProteinChipTM Reader (model PBSiI). Each sample was analyzed twice to confirm reproducibility in identifying the differentially expressed proteins.
  • the arrays were analyzed with the Ciphergen ProteinChip Reader (model PBSII).
  • the mass spectra of proteins were generated by using an average of 65 laser shots at a laser intensity of 230-280 arbitrary units.
  • the detection size range was between 3 and 20 kDa, with a maximum size of 25 kDa.
  • the laser was focused at 10 kDa.
  • the detector sensitivity was set at 8, and the laser intensity was set at 190.
  • the detection size range was between 20 and 150 kDa, with a maximum size of 250 kDa.
  • the laser was focused at 85 kDa.
  • the detector sensitivity was set at 9, and the laser intensity was set at 260 for the 1 :4 dilution and 280.
  • the mass-to-charge ratio ⁇ mlz) of each of the proteins captured on the array surface was determined according to externally calibrated standards (Ciphergen Biosystems): bovine insulin (5,733.6 Da), human ubiquitin (8,564.8 Da), bovine cytochrome c (12,230.9 Da), bovine superoxide dismutase (15,591.4 Da), bovine ⁇ -lactoglobulin A (18,363.3 Da), horseradish peroxidase (43,240 Da), BSA (66,410 Da), and chicken conalbumin (77,490 Da).
  • Proteins were removed from a 50 ⁇ i sample of CSF using a NanosepTM (Pall Corporation) centrifugal ultrafiltration device with a 1OkDa nominal molecular weight cut-off. An aliquot (5 ⁇ l) of the filtrate was desalted by solid-phase microextraction on a C18 ZipTipTM (Waters) and the peptides eluted with 0.1% formic acid/50 % aqueous acetonitrile (1 ⁇ l) directly into a nanospray tip
  • the nanospray tip was inserted into a nanoelectrospray ion source (Protana Engineering) attached to a quadupo!e-time-of-flight mass spectrometer (Qstar Pulsar i, Applied Biosystems-MDS Sciex) and full scan
  • TOF spectra were acquired for 5-10 minutes over the m/z range 350-1500 atomic mass units.
  • MS/MS spectra were acquired over the m/z range 50-1700 atomic mass units until sufficient signal:noise was attained.
  • the collision energy was optimized during data acquisition to give the widest range of fragment ions.
  • MS/MS data were manually interpreted to extract "sequence tags" which were used with BioAnalystTM software (Applied Biosystems) to search the NCBI NRDB database. The search results were confirmed by further manual interpretation of the MS/MS data.
  • the data were analyzed with PROTEINCHIPTM data analysis software version 3.0 (Ciphergen Biosystems). For each comparison, the raw intensity data were normalized by using the total ion current of all profiles in the groups compared. The peak intensities were normalized to the total ion current of m/z between 3,000 and 25,000 Da for the low molecuiar weight range and between 4,000 and 250,000 Da for the high molecular weight range.
  • the Biomarker Wizard application nonparametric calculations; Ciphergen Biosystems
  • Peak labeling was completed by using second-pass peak selection with 0.2% of the mass window, and estimated peaks were added. Sample statistics were performed on groups of profiles (normal vs. first onset psychosis). Protein differences (fold changes) were calculated among the various groups.
  • VGF peptide is upregulated in the prefrontal cortex of patients with schizophrenia.
  • Jablensky A Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry CHn Neurosci 250:274-285, 2000.
  • Horrobin DF Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Orthomol. Psychiatry 9:33-34, 1980.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention se rapporte à des biomarqueurs de troubles schizophréniques, de troubles bipolaire et de troubles psychotiques connexes. L'invention a également trait à des méthodes de diagnostic, de contrôle et de criblage associées aux biomarqueurs, ainsi qu'à des kits permettant de mettre en oeuvre de telles méthodes.
PCT/GB2006/050035 2005-02-14 2006-02-14 Biomarqueurs et leurs utilisations WO2006085122A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0502978.0 2005-02-14
GB0502978A GB0502978D0 (en) 2005-02-14 2005-02-14 Biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
WO2006085122A2 true WO2006085122A2 (fr) 2006-08-17

Family

ID=34356239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/050035 WO2006085122A2 (fr) 2005-02-14 2006-02-14 Biomarqueurs et leurs utilisations

Country Status (2)

Country Link
GB (1) GB0502978D0 (fr)
WO (1) WO2006085122A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064030A1 (fr) * 2008-12-01 2010-06-10 Cambridge Enterprise Limited Biomarqueurs
WO2011101666A1 (fr) 2010-02-16 2011-08-25 Loxbridge Research Llp Procédé de détection d'analyte à base d'oligonucléotide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064030A1 (fr) * 2008-12-01 2010-06-10 Cambridge Enterprise Limited Biomarqueurs
WO2011101666A1 (fr) 2010-02-16 2011-08-25 Loxbridge Research Llp Procédé de détection d'analyte à base d'oligonucléotide

Also Published As

Publication number Publication date
GB0502978D0 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
US7838246B2 (en) Biomarkers for schizophrenia
EP2657706B1 (fr) Biomarqueur pour des maladies de dysfonctionnement cognitif, et procédé de détection de maladies de dysfonctionnement cognitif à l'aide du biomarqueur
US20090176257A1 (en) Methods and Biomarkers for Diagnosing and Monitoring Psychotic Disorders
US11726099B2 (en) Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
US20100291597A1 (en) Secretogranin and vgf peptide biomarkers and uses thereof
EP2389587B1 (fr) Procédé diagnostic et prognostic concernant la maladie d'alzheimer
US20100223678A1 (en) protein isoforms of the pif-family and uses thereof
US20030092613A1 (en) Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
WO2011092504A2 (fr) Marqueurs biologiques
WO2006085122A2 (fr) Biomarqueurs et leurs utilisations
US20050130233A1 (en) Methods of diagnosing or treating Alzheimer's disease on basis of increased cerebrospinal fluid levels of nerve growth factor
WO2008107700A1 (fr) Diagnostic de troubles psychotiques
EP1173768B1 (fr) Procédés permettant le diagnostic, la prévison, l'évaluation de la progression ou du traitement de la dépression basés sur des quantités élevées de neurotrophin dans le liquide cérébrospinal.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06710159

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6710159

Country of ref document: EP